Importantly, APL cells treated with RA or with RA/tunicamycin degraded PML-RARα to a similar extent, which implies that increased PML-RARα degradation could not explain the therapeutic benefits of tunicamycin. This evidence concerns the gene PML and acute promyelocytic leukemia.